Integer Holdings has successfully finalized the acquisition of Oscor, Inc., a strategic move designed to significantly broaden the group’s cardiovascular and neurostimulation product portfolios. This transaction integrates a robust range of proprietary products, including steerable sheaths and cardiac leads, into the acquirer’s existing medical device outsource framework. The strategic rationale for the move centers on the acquisition of specialized technical capabilities and a vast intellectual property portfolio that deepens relationships with existing Tier 1 customers while providing access to emerging growth companies. By incorporating the target’s established brand and its research and development expertise, the organization bolsters its "concept-to-commercialization" value proposition. A key component of the integration is the addition of the target’s manufacturing presence in the Dominican Republic, which provides high-efficiency, low-cost production capacity to support the group’s global expansion. This partnership reinforces the group’s standing as a primary technical enabler for the cardiac rhythm management and neuromodulation industries, ensuring the strategic depth required to exceed market growth rates in fast-growing clinical segments like structural heart and electrophysiology.

The transaction values OSCOR at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.